Field Notes.

October 5, 2026

Amprius Rents Its Battery Factories. Every New Plant Has to Be Qualified Again.

Amprius designs silicon-anode drone cells and rents the factories that build them, now adding CAMINUS in Indianapolis with volume planned for early 2027. Renting moves the capital off the books, but each plant still has to be qualified format by format, and the company should own the records that make the next plant faster.

October 4, 2026

The FDA Approved a Heart Valve That Grows With Children. Proving It Saves Surgeries Takes a Decade.

The FDA approved Edwards' Autus valve, which goes into toddlers at about 13 millimeters and can be balloon-expanded toward 22 as they grow. The six-month data shows the valve works, and the promise of fewer surgeries runs on a ten-year follow-up.

October 3, 2026

Agility Robotics Built Its Name on Legs. Its Digit 5 Launch Showed Wheels.

Agility Robotics built its name on legs, then showed a wheeled rendering near the end of its Digit 5 launch video. Its filings show $1.8 million of 2025 revenue and $300 million in orders from a single customer, which leaves the next form factor open while it is still cheap to change.

October 2, 2026

Integra’s Flooded Plant Shows What Inventory, a Second Source and Insurance Can’t Cover

Integra LifeSciences cut its 2026 guidance after a July flood at its Cincinnati plant, which won't return to full manufacturing until the second quarter of 2027. Inventory, alternate sources for certain products and insurance each protect something different, and none of them keeps product reaching the customer. A founder who makes a product in one place can count the weeks before customers have to switch.

October 1, 2026

Terumo Is Buying Arsenal Medical Before Its Pivotal Trial Has Data. Medtronic Paid for the Proof.

Terumo Neuro agreed to buy Arsenal Medical while NeoCast, Arsenal's liquid embolic for chronic subdural hematoma, is still investigational and its pivotal trial is enrolling. The trial has to show NeoCast is no worse than Medtronic's Onyx, and Medtronic had already run the trial showing the procedure beats surgery alone. Arsenal tested its material in two uses, and the one that drew a buyer was the one another company had proved.

September 30, 2026

The FDA Would Credential Generative AI Like a Clinician. You Still Answer for a Model You Don’t Own.

The FDA's device center floated a competency-based review for generative AI devices, modeled on how clinicians are credentialed, with more monitoring after launch. Its proposed Foundation Model Master File is voluntary, and the device maker still answers for a model it didn't build. Founders putting a chatbot or agent in front of clinicians can settle version control in the vendor contract first.

September 29, 2026

Microbot’s FDA-Cleared Robot Now Meets the Hospital’s Value Analysis Committee Earlier

Microbot Medical's LIBERTY robot is FDA-cleared and on full market release, and the company now brings hospital value analysis committees into each sale earlier, citing a four-to-six-month review. The committee weighs per-case cost, which a startup can start answering in its design review.